|
MechanismCD163 inhibitors |
Active Org.- |
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.TH |
First Approval Date01 Jan 1997 |
A Phase I/II Clinical Study of WF 10 IV Solution ( TCDO ) in Patients With HIV Infection
To evaluate the clinical toxicity, safety, and MTD of WF 10 ( TCDO ) intravenous solution administered to patients with HIV infection. To evaluate the potential anti-HIV activity of TCDO.
Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of WF 10 IV Solution ( TCDO ) in the Management of Patients With Advanced HIV Disease
The purpose of this study is to see if it is safe and effective to give WF 10 (TCDO) to patients with advanced HIV disease who cannot or will not take zidovudine, didanosine, zalcitabine, or stavudine. This study also examines how TCDO affects the levels of HIV in the body. TCDO is a solution delivered through a vein.
100 Clinical Results associated with Oxo Chemie(Thailand) Co.,Ltd
0 Patents (Medical) associated with Oxo Chemie(Thailand) Co.,Ltd
100 Deals associated with Oxo Chemie(Thailand) Co.,Ltd
100 Translational Medicine associated with Oxo Chemie(Thailand) Co.,Ltd